Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies

CONCLUSIONS: Switching therapy, within or out of class, is the most successful strategy to regain and maintain clinical remission upon immunogenicity. When switching to another anti-TNF, concomitant immunomodulatory therapy should be started or continued to prevent repeated immunogenic loss of response. Anti-TNF dose escalation with concomitant immunomodulator optimisation is the fastest and most effective strategy to suppress ADA.PMID:37961895 | DOI:10.1080/00365521.2023.2278424

Source: Scandinavian Journal of Gastroenterology - November 14, 2023 Category: Gastroenterology Authors: Suzanne I Anjie Jurij Hanzel Krisztina B Gecse Geert R D'Haens Johannan F Brandse Source Type: research